Bevacizumab in Glaucoma: Where do We Stand?

The use of antivascular endothelial growth factors such as bevacizumab and ranibizumab has brought about a revolution in management protocols of various ophthalmic disorders. A lot has been written about these agents, still lacunae exist in our understanding due to paucity of randomized control tria...

Descripción completa

Detalles Bibliográficos
Autor principal: Khanna, Anjani
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Jaypee Brothers Medical Publishers 2012
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5161771/
https://www.ncbi.nlm.nih.gov/pubmed/28028350
http://dx.doi.org/10.5005/jp-journals-10008-1110
_version_ 1782482108383494144
author Khanna, Anjani
author_facet Khanna, Anjani
author_sort Khanna, Anjani
collection PubMed
description The use of antivascular endothelial growth factors such as bevacizumab and ranibizumab has brought about a revolution in management protocols of various ophthalmic disorders. A lot has been written about these agents, still lacunae exist in our understanding due to paucity of randomized control trials with large number of patients. This brief review attempts to throw light on the clinical applications of these molecules for glaucoma. HOW TO CITE THIS ARTICLE: Khanna A. Bevacizumab in Glaucoma: Where do We Stand? J Current Glau Prac 2012;6(2):75-78.
format Online
Article
Text
id pubmed-5161771
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Jaypee Brothers Medical Publishers
record_format MEDLINE/PubMed
spelling pubmed-51617712016-12-27 Bevacizumab in Glaucoma: Where do We Stand? Khanna, Anjani J Curr Glaucoma Pract Review Article The use of antivascular endothelial growth factors such as bevacizumab and ranibizumab has brought about a revolution in management protocols of various ophthalmic disorders. A lot has been written about these agents, still lacunae exist in our understanding due to paucity of randomized control trials with large number of patients. This brief review attempts to throw light on the clinical applications of these molecules for glaucoma. HOW TO CITE THIS ARTICLE: Khanna A. Bevacizumab in Glaucoma: Where do We Stand? J Current Glau Prac 2012;6(2):75-78. Jaypee Brothers Medical Publishers 2012 2012-08-16 /pmc/articles/PMC5161771/ /pubmed/28028350 http://dx.doi.org/10.5005/jp-journals-10008-1110 Text en Copyright © 2012; Jaypee Brothers Medical Publishers (P) Ltd. This work is licensed under a Creative Commons Attribution 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by/3.0/
spellingShingle Review Article
Khanna, Anjani
Bevacizumab in Glaucoma: Where do We Stand?
title Bevacizumab in Glaucoma: Where do We Stand?
title_full Bevacizumab in Glaucoma: Where do We Stand?
title_fullStr Bevacizumab in Glaucoma: Where do We Stand?
title_full_unstemmed Bevacizumab in Glaucoma: Where do We Stand?
title_short Bevacizumab in Glaucoma: Where do We Stand?
title_sort bevacizumab in glaucoma: where do we stand?
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5161771/
https://www.ncbi.nlm.nih.gov/pubmed/28028350
http://dx.doi.org/10.5005/jp-journals-10008-1110
work_keys_str_mv AT khannaanjani bevacizumabinglaucomawheredowestand

Ejemplares similares